FDC Ltd Q2 FY2023 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/h4nk4k9zeh9bkk294p0z7vji.pdf

Key Takeaways


The Primary-Secondary Sales Gap

Tikkha: "Our endeavour over a period of time is to mitigate this seasonality part of it by diversifying our portfolio and create newer avenues for our existing brands in the off season scenario."

Gross Margin: Pressure, Price Hikes, and the Raw Material Overhang

Jain: "Unless we see a drop or correction in the raw material and the packing material prices."

Export Surge and the US Ophthalmic Bet


Portfolio Diversification and the Seasonality Problem

Tikkha: "If I was to do Rs.100 sale that percentage will remain the same because you try to grow in each quarter equally looking at the opportunity which is available so that percentage might not change but yes we are trying to get some significance out of each quarter and each month for some of our products..."

Costs, Capex, and Working Capital

Jain: "It is very close to peak, I do not think so there will be any further increase on our working capital cycle."

Guidance & Commitments

CommitmentSpecificsTimeline
Primary-secondary sales gap closureAIOCD and internal growth numbers to converge as COVID-era trade inventory stabilizesQ3 FY23
Gross margin stabilizationFull benefit of scheduled price hikes to flow through; stabilization expected, but no expansion unless raw material prices correctQ3 and Q4 FY23
Opex rationalizationAdvance procurement of sales and marketing materials (~₹10 Cr impact in H1) to normalizeQ3 and Q4 FY23
Waluj plant US commercializationEquipment shift ~Jan 2; installation ~1 month; US FDA approvals ~18 months from commissioning; commercial production thereafter~2 years
International formulation revenue target₹450-500 Cr with heavy marginsBy end of FY2025
Overall company CAGR targetAt least 15-18% topline and bottom-line CAGRNext 3-5 years
Nutraceutical portfolio scaleConfident of closing current year at ₹68-70 Cr; ₹100 Cr basket as aspirationFY23 / medium term

Key Metrics

MetricQ2 FY23
Revenue growth12% YoY; 11% for H1 FY23
Domestic formulation revenue growth6% YoY; like-to-like growth would have been 11–12% excluding prior-year COVID therapy products
Export formulation revenue growth68% YoY for Q2; 48% for H1
Export API revenue growth31% YoY for Q2; 28% for H1
EBITDA margin18%, down from prior year
Gross margin impact from raw and packing material2% decline YoY, absolute impact of ₹23 cr for the quarter
Gross margin QoQ improvement~1% improvement from Q1 FY23 to Q2 FY23
Employee cost20% of revenue, marginally lower YoY owing to increased revenue base
Export incentive recorded in H1₹32 cr
Secondary sales growth (IQVIA)13.5% YoY during Q2 FY23
MAT volume growth5.9%
MAT price growth5.3%
MAT new product growth1.4%
PCPM (fee for productivity)~₹3.5 lakh per MR per month, largely flat YoY
MR count~3,600; 550 added for new derma division
Domestic sales under price control (NLEM)~46%
Electral MAT milestoneCrossed ₹350 cr on MAT September 2022 basis
Electral market share74%
Zifi market share (MAT)24.7%, up from 23.9% in September 2020
Enerzal market share42%+
Zifi CV market share49.3%
Zifi O market share14.6%
H1 brand growth: Electral30.5%
H1 brand growth: Enerzal37.9%
H1 brand growth: Zifi11.1%
H1 brand growth: Vitcofol14.6%
H1 brand growth: Zifi CV15.7%
Nutraceutical division (Nutritica) expected full-year volume₹68–70 cr, up from ~₹32 cr two years prior
International formulation expected full-year revenue₹200–220 cr
International business target by end of FY2025₹450–500 cr with heavy margins
Overall company CAGR target (next 3–5 years)15–18% for both topline and bottom line
Q2 FY23 exports topline₹75 cr
Working capital days~67 days on trailing 12-month basis, up from 59 days in FY22
Price increase benefit for H1~₹40–45 cr, effective from ~May onwards; net benefit closer to ₹30 cr (per an analyst's math)
Incremental gross margin Q2 FY23 vs Q2 FY22₹21 cr positive, with ~₹30 cr from price increases, ~₹15 cr from export formulation, offset by ~₹23 cr raw/packing material cost increase